242 related articles for article (PubMed ID: 32044043)
1. Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.
Sultana R; Kataki AC; Barthakur BB; Sarma A; Bose S
Curr Probl Cancer; 2020 Oct; 44(5):100556. PubMed ID: 32044043
[TBL] [Abstract][Full Text] [Related]
2. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
4. Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes.
Yang Q; Liu HY; Liu D; Song YQ
Asian Pac J Cancer Prev; 2015; 16(8):3229-32. PubMed ID: 25921124
[TBL] [Abstract][Full Text] [Related]
5. Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India.
Sultana R; Kataki AC; Borthakur BB; Basumatary TK; Bose S
Gene; 2017 Jul; 621():51-58. PubMed ID: 28414093
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
7. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients.
Dehghani M; Keshavarz P; Talei A; Akrami M; Tahmasebi S; Safaie A; Ghanbari M
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3027-3032. PubMed ID: 33112563
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer.
Li Q; Zheng ZC; Ni CJ; Jin WX; Jin YX; Chen Y; Zhang XH; Chen ED; Cai YF
Ann Clin Lab Sci; 2018 Jan; 48(1):40-44. PubMed ID: 29530995
[TBL] [Abstract][Full Text] [Related]
11. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
de Gregorio A; Friedl TWP; Hering E; Widschwendter P; de Gregorio N; Bekes I; Janni W; Dayan D; Huober JB
Oncology; 2021; 99(12):780-789. PubMed ID: 34535596
[TBL] [Abstract][Full Text] [Related]
12. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
[TBL] [Abstract][Full Text] [Related]
14. LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target.
Bodoor K; Almomani R; Alqudah M; Haddad Y; Samouri W
Asian Pac J Cancer Prev; 2020 May; 21(5):1453-1458. PubMed ID: 32458655
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
18. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
[TBL] [Abstract][Full Text] [Related]
19. Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery.
Chung A; Gangi A; Mirocha J; Giuliano A
Ann Surg Oncol; 2015 Apr; 22(4):1128-32. PubMed ID: 25300606
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
